[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$gpcr Graphic](https://lunarcrush.com/gi/w:26/t:$gpcr.png) $gpcr

$GPCR is attracting attention with positive sentiment, but investors are watching for the next move regarding safety and potential acquisition. The company's lead drug is under scrutiny, with the market focused on its safety profile and potential for big pharma acquisition.

### About $gpcr
A pharmaceutical company focused on developing novel therapeutics, particularly in the area of GLP-1 receptor agonists for metabolic diseases.  

### Insights [#](/topic/$gpcr/insights)
- $gpcr sentiment is up XXXXX% from the previous week.

### Engagements: XXX [#](/topic/$gpcr/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/interactions.tsv)  
**Current Value**: XXX  
**Daily Average**: XXXXXX  
**1 Week**: XXXXX -XX%  
**1 Month**: XXXXXXX -XX%  
**1-Year High**: XXXXXXX on 2025-06-25  
**1-Year Low**: XX on 2025-09-14  

| Social Network | X   |
| -------------- | -   |
| Engagements    | XXX |
  

  
  
### Mentions: XX [#](/topic/$gpcr/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/posts_active.tsv)  
**Current Value**: XX  
**Daily Average**: XX  
**1-Year High**: XXX on 2025-08-22  
**1-Year Low**: X on 2025-09-14  

| Social Network | X  |
| -------------- | -  |
| Mentions       | XX |
  

  
  
### Creators: XX [#](/topic/$gpcr/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning $gpcr in the last XX hours which is no change from in the previous XX hours
**Daily Average**: XX  
**1-Year High**: XXX on 2025-06-27  
**1-Year Low**: X on 2025-09-14  

The most influential creators that mention $gpcr in the last XX hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@RyanSmitty197](/creator/twitter/RyanSmitty197) | X    | XXX       | X     | XX          |

[View More](/list/creators/$gpcr/100)
  
  
### Sentiment: XX% [#](/topic/$gpcr/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$gpcr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$gpcr/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XXX% +25%  
**1 Month**: XX% -XX%  
**1-Year High**: XXX% on 2025-05-13  
**1-Year Low**: XX% on 2025-10-05  

**Most Supportive Themes**
- **GLP-1 Therapy Benefits:** (45%) Posts highlight the positive impacts of GLP-1 therapy, including weight loss and improved health markers.
- **Positive Sentiment on $GPCR:** (25%) Several posts express optimism about $GPCR's potential, particularly regarding its CEO and market opportunity.
- **Broader GLP-1 Market Discussion:** (15%) Discussions about the broader GLP-1 market, including comparisons with competitors and potential acquisitions.
  
**Most Critical Themes**
- **Safety Concerns and Side Effects:** (10%)  Mentions of potential side effects and safety concerns associated with GLP-1 therapies.
- **Comparison to Competitors:** (5%)  Comparisons to competitors, with some questioning $GPCR's efficacy and potential for success.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %  |
| ------- | -------- | -   | ------- | -   | -------- | -  |
| X       | XXX      | XX% | XXX     | XX% | X        | X% |
|         |          |     |         |     |          |    |
| Total   | XXX      | XX% | XXX     | XX% | X        | X% |
  


**Top assets mentioned**
In the posts about $gpcr in the last XX hours

[Viking Therapeutics, Inc (VKTX)](/topic/$vktx)
[Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr)
[Eli Lilly and Company (LLY)](/topic/eli-lilly)
[Cytokinetics Inc. (CYTK)](/topic/$cytk)
[Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/dyne-therapeutics)
[Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn)
[Bitcoin Incognito (XBI)](/topic/$xbi)
[Pfizer, Inc. (PFE)](/topic/$pfe)
[Eli Lilly and Company (LLY)](/topic/$lly)
[Novo-Nordisk (NVO)](/topic/$nvo)

**Top topics mentioned**
In the posts about $gpcr in the last XX hours

[stocks healthcare](/topic/stocks-healthcare), [$vktx](/topic/$vktx), [$mtsr](/topic/$mtsr), [eli lilly](/topic/eli-lilly), [$cytk](/topic/$cytk), [dyne therapeutics](/topic/dyne-therapeutics), [$dyn](/topic/$dyn), [$xbi](/topic/$xbi), [$pfe](/topic/$pfe), [$lly](/topic/$lly), [$nvo](/topic/$nvo), [behind the](/topic/behind-the), [coins dao](/topic/coins-dao), [$psnl](/topic/$psnl), [$akro](/topic/$akro), [$mstr](/topic/$mstr), [stocks technology](/topic/stocks-technology), [acquisition](/topic/acquisition), [$atxs](/topic/$atxs), [$elvn](/topic/$elvn), [$vik](/topic/$vik), [number of](/topic/number-of), [weight loss](/topic/weight-loss), [$azn](/topic/$azn), [$wves](/topic/$wves), [gsk plc](/topic/gsk-plc), [$gsk](/topic/$gsk), [$bbc](/topic/$bbc), [$janx](/topic/$janx), [$agio](/topic/$agio), [alt aptoslaunch token](/topic/alt-aptoslaunch-token), [$alt](/topic/$alt), [$alec](/topic/$alec), [$advm](/topic/$advm), [$mrus](/topic/$mrus), [$srrk](/topic/$srrk), [$tnxp](/topic/$tnxp), [$crnx](/topic/$crnx), [$fate](/topic/$fate), [$aimd](/topic/$aimd), [stocks](/topic/stocks), [$insm](/topic/$insm), [$nktr](/topic/$nktr), [post it](/topic/post-it), [superrare](/topic/superrare), [superrarebears](/topic/superrarebears), [coins solana ecosystem](/topic/coins-solana-ecosystem), [novo](/topic/novo), [$cdtx](/topic/$cdtx), [$dhr](/topic/$dhr), [stocks financial services](/topic/stocks-financial-services), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$crvs](/topic/$crvs), [$lrmr](/topic/$lrmr), [$unh](/topic/$unh), [$lulu](/topic/$lulu), [$iova](/topic/$iova), [$drug](/topic/$drug), [$ewtx](/topic/$ewtx), [$nari](/topic/$nari), [investment](/topic/investment)

### Top Social Posts [#](/topic/$gpcr/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Back in $GPCR & $LLY calls. Biotech is bubbly but run still got legs based on some indicators. Affordability will matter for Trump deals. Thesis for me is small molecule obesity plays (for GPCR safety gotta check out or they get BO before data) or low COGS peptides (Metsera BO)"  
[X Link](https://x.com/Optimistic24228/status/1979279188831109220) [@Optimistic24228](/creator/x/Optimistic24228) 2025-10-17T20:11Z XXX followers, XXX engagements


"$TNXP $CRNX $GPCR $FATE $AIMD $VTGN are my top bio pharma plays"  
[X Link](https://x.com/Radzikowski/status/1979225486804029869) [@Radzikowski](/creator/x/Radzikowski) 2025-10-17T16:38Z XXX followers, XXX engagements


"$LLY Likely just bluster trying to strong arm Lilly into giving big discounts. Due to the number of fat asses in the US weight loss drugs need to be a lot cheaper. CEO of $GPCR has mentioned the cost advantage of their oral therapy many times"  
[X Link](https://x.com/RyanSmitty197/status/1979124762120007852) [@RyanSmitty197](/creator/x/RyanSmitty197) 2025-10-17T09:58Z XXX followers, XXX engagements


"$GPCR Not saying a buyout is imminent but low volume selloffs often mean nothing. I had a large position in $NARI which was bought out for a fat premium in January. Saw Inari trade red X out of X days for the month leading up to the deal announcement. Bled $XX to $XX then $79"  
[X Link](https://x.com/RyanSmitty197/status/1978909117956661732) [@RyanSmitty197](/creator/x/RyanSmitty197) 2025-10-16T19:41Z XXX followers, XXX engagements